BASILEA N/ CH0011432447 /
| 15/11/2024 17:31:42 | Chg. -0.700 | Volume | Bid17:40:00 | Ask17:40:00 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 40.000CHF | -1.72% | 36,116 Turnover: 1.44 mill. |
39.600Bid Size: 213 | 40.200Ask Size: 200 | 523.99 mill.CHF | - | 45.98 |
GlobeNewswire
27/08
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) an...
GlobeNewswire
21/08
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
13/08
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and prof...
GlobeNewswire
20/06
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
GlobeNewswire
16/05
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
03/05
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire
24/04
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire
09/04
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
04/04
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire
11/03
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire
13/02
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
19/01
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire
11/12/2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
20/11/2023
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire
13/11/2023
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire
31/10/2023
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire
19/10/2023
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
17/10/2023
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire
02/10/2023
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
